ストックスクリーナーアプリを入手
36.01
3.12%
-1.16
前日終値:
$37.17
開ける：
$37.83
24時間の取引高:
643.18K
Relative Volume:
0.57
時価総額：
$2.11B
収益：
$13.05M
当期純損益:
$-60.54M
株価収益率:
-31.04
EPS:
-1.16
ネットキャッシュフロー:
$-37.82M
1週間 パフォーマンス:
-0.99%
1か月 パフォーマンス:
-11.98%
6か月 パフォーマンス:
-19.80%
1年 パフォーマンス:
+174.05%
1日の値動き範囲:
$35.53
$38.42
1週間の範囲:
$35.53
$38.42
52週間の値動き範囲:
$13.20
$71.71
Janux Therapeutics Inc Stock (JANX) Company Profile
名前
Janux Therapeutics Inc
セクター
電話
(858) 751-4493
住所
10955 VISTA SORRENTO PARKWAY, SAN DIEGO
JANX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
JANX
Janux Therapeutics Inc
|
36.01 | 2.11B | 13.05M | -60.54M | -37.82M | -1.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Janux Therapeutics Inc Stock (JANX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-03 | 繰り返されました | BTIG Research | Buy |
| 2024-12-03 | 繰り返されました | H.C. Wainwright | Buy |
| 2024-11-22 | 開始されました | Leerink Partners | Outperform |
| 2024-10-24 | 開始されました | UBS | Buy |
| 2024-09-06 | 開始されました | Stifel | Buy |
| 2024-05-30 | 開始されました | Scotiabank | Sector Perform |
| 2024-03-21 | 開始されました | BTIG Research | Buy |
| 2024-03-20 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-04-06 | 開始されました | Wedbush | Outperform |
| 2022-11-14 | 開始されました | William Blair | Outperform |
すべてを表示
Janux Therapeutics Inc (JANX) 最新ニュース
Trend Tracker for (JANX) - Stock Traders Daily
Janux Therapeutics, Inc. (NASDAQ:JANX) Shares Acquired by Lester Murray Antman dba SimplyRich - MarketBeat
abrdn plc Acquires New Holdings in Janux Therapeutics, Inc. (NASDAQ:JANX) - MarketBeat
Janux Therapeutics, Inc. (NASDAQ:JANX) Receives $89.90 Average PT from Analysts - MarketBeat
Janux Therapeutics, Inc. (NASDAQ:JANX) Receives $89.90 Average Price Target from Brokerages - Defense World
Quarterly Snapshot: Quick and Current Ratios for Janux Therapeutics Inc (JANX) - The Dwinnex
Mid-Cap Biopharma’s Biggest Winners And Losers Of 2024 - insights.citeline.com
Andrew Hollman Meyer Sells 3,334 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX) Stock - MarketBeat
Janux Therapeutics (NASDAQ:JANX) Stock Price Up 6.9%Still a Buy? - MarketBeat
Janux Therapeutics (NASDAQ:JANX) Shares Down 4.2%Here's Why - MarketBeat
Janux Therapeutics Inc (NASDAQ: JANX) Gain Of 80.16% Compared To 52-Week Low; YTD Fall -26.47% – What Should You Do Now? – Marketing Sentinel - Marketing Sentinel
Janux Therapeutics Inc (JANX): Is It Worth A Small Bite At $40.68? - Stocks Register
Janux therapeutics' chief business officer sells shares worth $140,999 - MSN
The Volatility of Janux Therapeutics Inc’s (JANX) Stock: A -9.18% Ratio for the Week - The News Heater
Janux Therapeutics Inc (JANX) is looking forward to a strong quarter - SETE News
A Tale of Resilience: Janux Therapeutics Inc Amid Stock Market Turbulence - The InvestChronicle
Janux therapeutics’ chief business officer sells shares worth $140,999 By Investing.com - Investing.com Nigeria
Janux therapeutics' chief business officer sells shares worth $140,999 By Investing.com - Investing.com South Africa
Insider Sell Alert: Andrew Meyer Sells Shares of Janux Therapeutics Inc (JANX) - GuruFocus.com
Short Interest in Janux Therapeutics, Inc. (NASDAQ:JANX) Rises By 19.8% - MarketBeat
Janux Therapeutics Inc (JANX) stock on the rise: An overview - US Post News
Market Recap: Janux Therapeutics Inc (JANX)’s Negative Momentum, Closing at 42.07 - The Dwinnex
Monitoring Janux Therapeutics Inc (JANX) after recent insider movements - Knox Daily
Nisa Investment Advisors LLC Cuts Position in Janux Therapeutics, Inc. (NASDAQ:JANX) - MarketBeat
Nisa Investment Advisors LLC Trims Stake in Janux Therapeutics, Inc. (NASDAQ:JANX) - Defense World
Core Scientific's chief legal officer sells $410,473 in stock - MSN
Thomas Barnes named CEO of Averna - BioCentury
Advanced Renal Cell Carcinoma Pipeline 2024: Comprehensive - openPR
JPMorgan Chase & Co. Decreases Stock Position in Janux Therapeutics, Inc. (NASDAQ:JANX) - Defense World
How to Take Advantage of moves in (JANX) - Stock Traders Daily
Janux Therapeutics Promotes Zachariah McIver, D.O., Ph.D. to Chief Medical Officer - BioSpace
Janux Therapeutics, Inc. Promotes Zachariah McIver to Chief Medical Officer -January 24, 2025 at 04:01 pm EST - Marketscreener.com
Janux Therapeutics Names McIver as Chief Medical Officer - MarketWatch
Janux Therapeutics (NASDAQ:JANX) Trading 6.2% HigherHere's What Happened - MarketBeat
Cantor Fitzgerald Forecasts JANX FY2025 Earnings - Defense World
Cantor Fitzgerald Predicts JANX FY2025 Earnings - MarketBeat
Janux Therapeutics surges amid report of takeover interest - MSN
Janux Therapeutics Inc (JANX) 財務データ
収益
当期純利益
現金流量
EPS
0.27%
3.05%
大文字化:
|
ボリューム (24 時間):